Relationship between rate of infusion and reinforcing strength of oxycodone in humans
- PMID: 19736900
- DOI: 10.5055/jom.2009.0022
Relationship between rate of infusion and reinforcing strength of oxycodone in humans
Abstract
The rate of drug delivery to the central nervous system is believed to be an important predictor of the reinforcing strength of a drug. However, only a few studies have directly examined the relationship between drug-taking behavior and rate of drug administration. The purpose of the present experiment was to determine whether manipulating the infusion rate of a fixed dose of opioid alters its reinforcing effectiveness in humans. Twelve heroin-dependent participants (11 male, one female) completed the 2.5-week inpatient study. During test days, participants received $20 and a dose of drug (0 or 40 mg oxycodone administered intravenously over 2, 15, 30, 60, or 90 minutes) in random order during a morning sample session. Participants then worked for the sampled dose and/or money amount during an afternoon choice session by making finger presses on a computer mouse. Under these conditions, 40 mg oxycodone served as a reinforcer only when it was delivered over 2 and 15 minutes. Subjective ratings of drug liking, good effect, and high were similar to the self-administration results. Peak plasma levels of oxycodone generally occurred at the end of each infusion, eg, 2 minutes for the 2-minute infusion duration. Extended-release opioid medications are commonly prescribed for treating pain. The present results provide empirical support for the development of extended-release opioid medications that are difficult to convert into more rapid-acting forms. Specifically, these "abuse-deterrent formulations" could prevent patients from tampering with their medications to enhance their euphoric and reinforcing effects.
Similar articles
-
Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).Pain Pract. 2016 Mar;16(3):334-44. doi: 10.1111/papr.12280. Epub 2015 Jan 12. Pain Pract. 2016. PMID: 25639548
-
Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence.Neuropsychopharmacology. 2017 Aug;42(9):1825-1832. doi: 10.1038/npp.2017.70. Epub 2017 Apr 10. Neuropsychopharmacology. 2017. PMID: 28393896 Free PMC article. Clinical Trial.
-
Abuse liability of oxycodone as a function of pain and drug use history.Drug Alcohol Depend. 2010 Jun 1;109(1-3):130-8. doi: 10.1016/j.drugalcdep.2009.12.018. Epub 2010 Jan 15. Drug Alcohol Depend. 2010. PMID: 20079977 Free PMC article.
-
Oral Prolonged-Release Oxycodone/Naloxone for Managing Pain and Opioid-Induced Constipation: A Review of the Evidence.Pain Pract. 2018 Jun;18(5):647-665. doi: 10.1111/papr.12646. Epub 2017 Nov 28. Pain Pract. 2018. PMID: 28944983 Review.
-
An abuse-deterrent, microsphere-in-capsule formulation of extended-release oxycodone: alternative modes of administration to facilitate pain management in patients with dysphagia.Curr Med Res Opin. 2016 Dec;32(12):1975-1982. doi: 10.1080/03007995.2016.1222517. Epub 2016 Sep 26. Curr Med Res Opin. 2016. PMID: 27668546 Review.
Cited by
-
Update on prescription extended-release opioids and appropriate patient selection.J Multidiscip Healthc. 2013 Jul 23;6:265-80. doi: 10.2147/JMDH.S38562. Print 2013. J Multidiscip Healthc. 2013. PMID: 23900563 Free PMC article.
-
Hepatitis C infection in non-treatment-seeking heroin users: the burden of cocaine injection.Am J Addict. 2013 Nov-Dec;22(6):613-8. doi: 10.1111/j.1521-0391.2013.12058.x. Epub 2013 Jun 6. Am J Addict. 2013. PMID: 24131170 Free PMC article.
-
Relative Bioavailability, Intranasal Abuse Potential, and Safety of Benzhydrocodone/Acetaminophen Compared with Hydrocodone Bitartrate/Acetaminophen in Recreational Drug Abusers.Pain Med. 2018 May 1;19(5):955-966. doi: 10.1093/pm/pnx195. Pain Med. 2018. PMID: 29025138 Free PMC article.
-
Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments.Pharmacol Rev. 2023 Nov;75(6):1062-1118. doi: 10.1124/pharmrev.121.000506. Epub 2023 Jun 15. Pharmacol Rev. 2023. PMID: 37321860 Free PMC article. Review.
-
The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine/naloxone.Neuropsychopharmacology. 2011 Jan;36(2):411-22. doi: 10.1038/npp.2010.172. Epub 2010 Oct 27. Neuropsychopharmacology. 2011. PMID: 20980992 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources